Request the Full Paper

Throughout the campaign and into the early weeks of the new presidency, the Trump administration has sent mixed messages about health, insurance, and pharmaceuticals. As agency leadership is still being put in place, the administration’s priorities for federal health programs remain unclear.

Petauri is committed to promoting an environment that fosters scientific innovation, pricing based on value, and affordable access to care. Achieving these goals can seem daunting with an uncertain policy environment. We hope to cut through the fog by looking at the near-term goals of the Trump administration and assessing how changes in federal health programs may be leveraged to meet those broader goals.
 

In this memo, we:

            1) Capture what the new administration has or has not said, on key     issues relevant to the Pharmaceutical industry


            2) Highlight core structural features of each issue and how
                those features may prove to be catalysts or constraints on
                federal actions


            3) Assess the potential outcomes of any actions and likelihood
                of any near-term changes
            

By submitting my information, I give my consent to receive communications and other marketing emails from Petauri